Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 04, 2022

Effectiveness of Sotrovimab vs Molnupiravir for the Prevention of Severe COVID-19–Related Outcomes

BMJ: British Medical Journal


Additional Info

Disclosure statements are available on the authors' profiles:

BMJ: British Medical Journal
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
BMJ 2022 Nov 16;379(2022)e071932, B Zheng, ACA Green, J Tazare, HJ Curtis, L Fisher, L Nab, A Schultze, V Mahalingasivam, EPK Parker, WJ Hulme, SCJ Bacon, NJ DeVito, C Bates, D Evans, P Inglesby, H Drysdale, S Davy, J Cockburn, CE Morton, G Hickman, T Ward, RM Smith, J Parry, F Hester, S Harper, A Mehrkar, RM Eggo, AJ Walker, SJW Evans, IJ Douglas, B MacKenna, B Goldacre, LA Tomlinson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading